Secondary end point(s): Safety parameters:<br><br>·Olaratumab plus doxorubicin treatment and dosage used<br>·Treatment duration (number of cycles)<br>·General description of grade 3/4 adverse events<br>·Reason for discontinuation of treatment<br>·Discontinuation rate due to cardiac toxicity <br>(i.e. due to LVEF reduction by more than 20% or LVEF <45%)<br><br>Efficacy parameters:<br>•PFS: <br>PFS is defined as the time from the first dosing date of any study medication to the date of the first objectively documented tumor progression, as determined by investigators (per RECIST v1.1), or death due to any cause. Subjects who die without a reported prior progression will be considered to have progressed on the date of their death. Subjects who did not progress or die will be censored on the date of their last tumor assessment. Subjects who did not have any on study tumor assessments and did not die will be censored on the first dosing date of study medication. Subjects who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the last tumor assessment prior to initiation of the subsequent anti-cancer therapy. <br>•ORR: Objective Response Rate (ORR) defined as the number and percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). Best overall response (BOR) is defined as the best response designation, recorded between the date of first dose and the date of the initial objectively documented tumor progression per RECIST v1.1 or the date of subsequent therapy or death date, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination.<br>•DCR: Disease Control Rate (DCR) defined as the number and percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD), recorded between the date of first dose and the date of the initial objectively documented tumor progression per RECIST v1.1 or the date of subsequent therapy or death date, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the DCR determination.<br>•OS: OS is defined as the time from date of the first dosing date of any study medication to the date of death (due to any cause). Subjects who are alive will be censored at the last known alive dates.<br>;Timepoint(s) of evaluation of this end point: Secondary endpoints will be evaluated at the end of study